WeVote
Log In

Bill

Bill

HB 1335

Biomarker Testing

2025 Regular Session Introduced by Karen Gonzalez Pittman and 1 co-sponsor

HB 1335 required Florida insurers to cover biomarker testing for disease detection and treatment planning, but died in committee as the companion SB 2514 passed into law instead.

Died in Health & Human Services Committee, companion bill(s) passed, see SB 2514 (Ch. 2025-204)
#(adopted) #insurance #publichealth
0
WeVote Research Nonpartisan
Bill Summary · HB 1335

Legislative bill overview

HB 1335 sought to establish coverage and reimbursement requirements for biomarker testing in Florida, likely requiring insurance plans to cover genetic or molecular tests used to identify disease risk or treatment response. The bill was introduced by representatives Karen Gonzalez Pittman and Michael Owen and ultimately died in committee, though a companion bill (SB 2514) passed and became law.

Why is this important

Biomarker testing can significantly improve patient outcomes by enabling early disease detection, personalized treatment selection, and more precise medical decision-making. Coverage mandates directly affect healthcare access and costs for Floridians, as insurance reimbursement determines whether patients can afford these increasingly important diagnostic tools without substantial out-of-pocket expenses.

Potential points of contention

  • Insurance cost burden: Requiring coverage for biomarker tests increases healthcare premiums and insurer costs, with debate over which tests should be mandated versus optional coverage
  • Clinical utility standards: Disagreement over which biomarkers have sufficient scientific evidence to warrant mandatory coverage versus experimental or investigational tests
  • Implementation and scope: Uncertainty about which biomarker tests, conditions, and patient populations would be covered, affecting medical practice consistency across the state

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.